Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Research Reports

General Anesthesia Drugs Market is expected to reach a valuation of US$ 6.7 Billion by 2032

Published : , on

Rising geriatric population coupled with increasing incidences of chronic diseases lead to a surge in the number of surgeries performed which in turn augments the sales of general anesthesia drugs in the global market during the forecast period

NEWARK, Del: The general General Anesthesia Drugs Market is anticipated to reach a value of US$ 4.7 billion by the end of 2022 and to grow at a CAGR of 3.4% to US$ 6.7 billion by 2032. Propofol is the most popular drug class right now, with a market share of about 25.6% in 2021, according to a recent study by Future Market Insights.

Increasing geriatric population coupled with rising incidences of chronic illnesses have resulted in a surge in surgeries. With an increasing elderly population, a greater number of surgeries are conducted resulting in a high demand for anesthesia drugs. Furthermore, the healthcare expenditure is rising in developing and developed countries. Since, anesthesia is usually covered by health insurance for all medical procedures, the out-of-pocket cost for anesthesia for patients with medical insurance is around 10% to 50%. Hence, health insurance is advantageous for the general anesthesia market.

Ambulatory anesthesia delivers faster recovery from general anesthesia drugs, patients can leave the hospital earlier while also offering tremendous benefits to third-party payers, hospitals, healthcare providers, and patients. Again, there’s a surge in the number of ambulatory surgeries owing to constant progress in general anesthesia drugs and different techniques, along with the easy availability of short-acting anaesthetics with less side effects. This bodes well for the target market.

Request for a sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-388

The development of specific targeted drugs, the availability of technologically sophisticated drug delivery devices, and rising clinical trials for the development of general anesthesia drugs as well as expanding portfolio of the general anesthesia drugs will lead to the expansion of the general anesthesia drugs market during the forecast period.

“Rising geriatric population coupled with increasing incidences of chronic diseases lead to a surge in the number of surgeries performed which in turn augments the sales of general anesthesia drugs in the global market during the forecast period,” says an FMI analyst.  

Key Takeaways:

  • Increasing investment in clinical trials for the development of general anesthesia drugs will strengthen the market prospects for the same.
  • Side effects like amnesia, respiratory depression, high blood pressure, and others may negatively impact the market growth.
  • The U.S general anesthesia drugs market will record a 2.4% CAGR during the projected period.
  • Growing cancer cases drives the growth of the general anesthesia drugs market in China.
  • Propofol general anesthesia drugs segment will grow at a 4.2% CAGR.
  • Intravenous route of administration will grow at a 3.6% CAGR.

Competitive Landscape 

Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited, Hikama Pharmaceuticals plc, Abbott Laboratories, Avet Pharmaceuticals, Inc, Piramal Enterprises Limited, Par Pharmaceutical, Teva Pharmaceuticals, Viatris/Mylan, Novartis AG, GlaxoSmithKline plc, Gilead Sciences, Inc., Sanofi, Akorn, Apotex, and Heritage Pharmaceuticals Inc., among others are some of the major players in the Neuromuscular Blocking Drugs Market profiled in the full version of the report.

Leading market players are concentrating product development and new product releases to cater to the consumer demand. These businesses employ tactics like mergers, acquisitions, partnerships, and collaborations to expand their consumer base.

Ask the Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-388

More Insights into General Anesthesia Drugs Market Report

In its latest report, FMI offers an unbiased analysis of the global general anesthesia drugs market, providing historical data from 2014 to 2021 and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and scope, the market is segmented on the basis of drug class (propofol, sevoflurane, dexmedetomidine, desflurane, remifentanil, midazolam, others (sufentanil, fentanyl, ketamine, isoflurane, thiopental, etc.)), route of administration (intravenous anesthesia, inhaled anesthesia), end user (hospitals, ambulatory surgical centers, specialty clinics), and region.

According to the latest FMI reports, based on segmentation, the propofol general anesthesia drugs segment will dominate the market during 2022-2032. The intravenous route of administration and hospitals, in terms of end user, will also make significant contributions during the forecast period.

Based on region, the general anesthesia drugs market in Germany will exhibit substantial growth due to the availability of many lucrative opportunities. Growing geriatric population, high incidences of chronic diseases, and rising cost of healthcare will drive the market growth of the country during the forecast period.

Key Market Segments Covered in General Anesthesia Drugs Industry Research

By Drug Class:

  • Propofol
  • Sevoflurane
  • Dexmedetomidine
  • Desflurane
  • Remifentanil
  • Midazolam
  • Others – (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)

Use promo code ->> FMITODAY to get a flat 20% discount

By Route of Administration:

  • Intravenous Anesthesia
  • Inhaled Anesthesia

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

 Table of Content

  1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply-Side Trends

1.4. Analysis and Recommendations

  1. Market Overview

2.1. Market Coverage/ Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

Complete TOC with Report Preview: https://www.futuremarketinsights.com/reports/general-anesthesia-drugs-market 

Have a Look at Related Research Reports in the Healthcare Domain:

Cryoglobulinemia Treatment Market Size – The global cryoglobulinemia treatment market is expected to garner a market value of US$ 496 Million in 2023 and is expected to accumulate a market value of US$ 888.26 Million by registering a CAGR of 6% in the forecast period 2023 to 2033.

Healthcare Cloud Infrastructure Market Share – Newly-released Healthcare Cloud Infrastructure Market analysis report by Future Market Insights shows that global sales of Healthcare Cloud Infrastructure Market in 2022 were held at US$ 45.1 Billion. With a CAGR of 23.9%, the market is projected to reach a valuation of US$ 464.1 Billion by 2033.

Magnetic Resonance Imaging Coils Market Growth – Newly-released Magnetic Resonance Imaging Coils Market analysis report by Future Market Insights shows that global sales of Magnetic Resonance Imaging Coils in 2022 were held at US$ 8.5 Billion. With a CAGR of 8.3% from 2023 to 2033,

Lights for Dental Healthcare Market Demand – The global lights for dental healthcare market is forecasted to expand at 5.7% CAGR to reach a market valuation of US$ 1.28 billion by the end of 2033, up from US$ 704.4 million that was recorded for 2022.

Flexible Endoscopes Market Forecast – The global flexible endoscopes market is forecasted to expand at 6.4% CAGR to reach a market valuation of US$ 16.73 Billion by the end of 2033, up from US$ 8.44 Billion that was recorded for 2022.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedInTwitterBlogs | YouTube

For Sales Enquiries: [email protected]

Jesse Pitts has been with the Global Banking & Finance Review since 2016, serving in various capacities, including Graphic Designer, Content Publisher, and Editorial Assistant. As the sole graphic designer for the company, Jesse plays a crucial role in shaping the visual identity of Global Banking & Finance Review. Additionally, Jesse manages the publishing of content across multiple platforms, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune.

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post